Why YS Biopharma Stock Is Plunging Today

YS Biopharma YS stock is falling Monday after the company announced PIKA recombinant COVID-19 vaccine.

YS Biopharma announced interim Phase 2 safety and immunogenicity data for its PIKA recombinant COVID-19 Vaccine. 

The interim data were from the Phase 2 part of the Phase 2/3 head-to-head clinical study to evaluate PIKA recombinant COVID-19 vaccine vs. inactivated COVID-19 vaccine. 

The interim data analysis of the Phase 2 study presented that the trial met both primary and secondary endpoints, measured by geometric mean titers (GMTs) of neutralizing antibody against Omicron virus and by seroconversion rates on Day 7 and Day 14 post a booster dose administration.

The ongoing Phase 2/3 study was conducted in the Philippines and United Arab Emirates, which finished the enrollment of 300 and 5656 subjects for the Phase 2 and 3 trials, respectively. 

A booster dose of PIKA recombinant COVID-19 vaccine in participants who had previously received two or more doses of the inactivated COVID-19 vaccine elicited superior neutralizing immune responses against the Omicron virus to the responses in participants receiving a booster dose of the inactivated COVID-19 vaccine. 

The differences of multiple folds of GMTs were observed with a 95% confidence interval of neutralizing antibodies against the Omicron virus. 

Price Action: YS shares are down 35.30% at $3.10 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversGeneralCOVID-19 CoronavirusCOVID-19 Vaccinewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!